Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of new treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company’s technology includes two r cell platforms: Immune Cell therapy for treatment of a range of cancers using Tcm, TCR clonality, CAR-T and anti-PD-1 technologies, human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases (including osteoarthritis and tissue damage), various inflammatory diseases and metabolic diseases. It is conducting clinical studies for two stem cell based therapies to treat knee osteoarthritis (KOA) and Cartilage Defect (CD). It is conducting preclinical studies in Asthma, and Chronic Obstructive Pulmonary Disease (COPD).
